Findings reveal that access to compliant chat expands the engagement channel mix, more than doubling digital touchpoints with healthcare professionals (HCPs) while maintaining or increasing in-person meetings.
The report shows face-to-face engagements with HCPs have increased by 20% in Asia Pacific from the same time a year before while maintaining steady open and click rates on email interactions. This illustrates increased higher-quality engagement with HCPs through both digital and in-person channels.
Global Veeva Pulse data has also shown the value of compliant chat in facilitating more meaningful engagement with HCPs starting 30% of conversations with field teams. Often sent in the moment of need, compliant chats gain a rapid response from field teams in less than five minutes. This two-way communication delivers on HCP requests in real-time, creating the foundation for a service-focused engagement model that improves access and efficiency.
"To communicate effectively across digital channels, you need to focus on responsiveness, adding value with the ability to give customers what they need, exactly when they need it," says Dave Yates, global product director, GSK. "Having the insights and two-way communication capabilities to meet, connect, and share has given us a foundation for thinking about digital engagement on a whole new level."
In Asia, Veeva Pulse data shows that the region relies heavily on the use of Closed-Loop Marketing (CLM) in meetings, and digital tools such as video, chat and text. Veeva CLM is an add-on application enabling users to easily search and present content while automatically capturing key metrics and recording in CRM.
- Asia Pacific relies heavily on its use of CLM in meetings. 40% of in-person meetings with HCPs in Asia Pacific involve the use of CLM, as compared to 35% in the US and 25% in Europe. At 85%, the use of CLM in Veeva Engage compliant video meetings remains the preferred supplementary channel when engaging with HCPs.
- Channel mix remains diverse across markets in Asia with digital tools emerging as dominant methods of HCP engagement. Video, chat and text continue to grow in preference in Southeast Asia, India, and South Korea with more reps leveraging such channels.
Veeva Pulse shows that two-way communication channels increase the quality of HCP interactions:
- Inbound channels help to double digital engagement. The average global engagement channel mix is 78% in-person and 22% digital. However, biopharmas that add inbound channels, like compliant chat, expand their mix to 42% in-person and 58% digital. This more than doubles digital touchpoints while keeping the volume of in-person exchanges the same or better.
- HCPs start 30% of conversations with an inbound channel. When sending messages via compliant chat, HCPs are shown to get a response from field teams in less than five minutes — such as sending requested content and samples or scheduling a meeting. Compliant chat has clear advantages for HCPs over text or stand-alone chat apps that have compliance risks and disconnected data.
Hashtag: #Veeva #VeevaSystems #Healthcare #LifeSciences #Cloud #CRM #HCPEngagement
https://www.veeva.com/ap/
https://linkedin.com/company/veeva-systems-apac
The issuer is solely responsible for the content of this announcement.
About the Veeva Pulse Field Trends Report
Analyzing over 600 million HCP interactions and activities annually from more than 80% of commercial biopharma field teams worldwide, the Veeva Pulse Field Trends Report is the largest industry benchmark of its kind on HCP engagement. The analysis compiles real-time transactional data recorded in Veeva CRM and Veeva data products to deliver a view of engagement activity across life sciences. Indexed by Veeva quarterly, the data will help companies effectively and accurately benchmark performance to set the right, actionable goals for continued growth and impact.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.